# US 2016/0250272 A1 · Antiangiogenic use of liquid phytocomplexes from olive

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250272 A1
- Document ID: US20160250272A1
- Status: Published application
- Kind: A1
- Application number: 15/033,586
- Filed: 2014-10-31
- Published: 2016-09-01
- Earliest claimed: 2013-10-31
- Assignees: Fattoria La Vialla Di Gianni, Antonio E Bandino Lo Franco - Societa'agricola Semplice
- Applicants: Fattoria La Vialla Di Gianni, Antonio E Bandino Lo Franco - Societa'agricola Semplice
- Inventors: Gianni LO FRANCO; Adriana ALBINI; Massimo PIZZICHINI; Teresa ROSSI; Antonino BRUNO; Arianna PAGANI
- Web page: https://patentgrep.com/patent/US20160250272A1

## CPC

- A61K 36/63: Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/16: Inorganic salts, minerals or trace elements
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/351: not condensed with another ring
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2236/39: Complex extraction schemes, e.g. fractionation or repeated extraction steps
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to a phytocomplex or natural concentrate rich in polyphenolic compounds, such as hydroxytyrosol and 3,4-DHPA-EDA, derived from the vegetation waters of oil-bearing olives or from olive pomace resulting from the olive milling process for use in the treatment and prevention of angiogenesis and inflammation. In particular, the angiogenesis and inflammation to which reference is made is pathologic angiogenesis and inflammation, for example that which sustains the development and spread of a tumor or angiogenesis and inflammation tied to non-tumor pathologies. The present invention further relates to a beverage comprising the polyphenol concentrate and the use thereof in the treatment and prevention of angiogenesis and inflammation.

## Claims

### Claim 1

A method of using a composition comprising a concentrate of vegetation waters and/or olive pomace comprising hydroxytyrosol and 3,4-dihydroxyphenolethanol-elenolic acid di-aldehyde (3,4-DHPA-EDA) to treat and/or prevent angiogenesis, comprising the step of administering the composition to a patient in need thereof, wherein the composition treats and/or prevents angiogenesis.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the concentrate further comprises: at least one phenolic compound selected from: tyrosol, chlorogenic acid, β-hydroxyverbascoside, rutin, verbascoside, and luteolin; and/or at least one metal selected from: sodium, calcium, magnesium and potassium; and/or at least an anion selected from: chlorides, sulphates, phosphates and nitrates; and/or at least one carbohydrate selected from: glucose, fructose, mannitol and sucrose; and/or nitrogen.

### Claim at position 3

3-6. (canceled)

### Claim 7

A method of using a concentrate of vegetation waters and/or olive pomace, to treat and/or prevent angiogenesis, comprising the step of administering said concentrate to a patient in need thereof,
wherein the concentrate treats and/or prevents angiogenesis, and
wherein the method is prepared by a process for producing the concentrate of vegetation water and/or olive pomace comprising the steps of:
(i) microfiltering a sample of vegetation water and/or olive pomace to obtain the concentrate and a permeate of microfiltration; and
(ii) concentrating by reverse osmosis the microfiltration permeate of step (i).

### Claim 8 (depends on 7)

The method according to claim 7, wherein the angiogenesis is a pathologic tumor or non-tumor angiogenesis.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the angiogenesis is a non-tumor angiogenesis selected from rheumatic diseases; inflammatory diseases of the colon-rectum; bronchial pathologies; liver diseases; diseases of the prostate; mucositis; dermatitis or pre-neoplastic lesions.

### Claim 10

A method of using a composition comprising a concentrate of vegetation waters and/or olive pomace comprising hydroxytyrosol and 3,4-dihydroxyphenolethanol-elenolic acid di-aldehyde (3,4-DHPA-EDA) to inhibit tumor blood vessel formation, comprising the step of administering the composition to a patient in need thereof, wherein the composition inhibits tumor blood vessel formation.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition is a beverage.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the angiogenesis is a pathologic tumor or non-tumor angiogenesis.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The method according to claim 13, wherein the angiogenesis is a non-tumor angiogenesis selected from rheumatic diseases; inflammatory diseases of the colon-rectum; bronchial pathologies; liver diseases; diseases of the prostate; mucositis; dermatitis or pre-neoplastic lesions.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the angiogenesis is a pathologic tumor or non-tumor angiogenesis.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the angiogenesis is a non-tumor angiogenesis selected from rheumatic diseases; inflammatory diseases of the colon-rectum; bronchial pathologies; liver diseases; diseases of the prostate; mucositis; dermatitis or pre-neoplastic lesions.

### Claim 18 (depends on 7)

The method according to claim 7, wherein the concentrate further comprises: at least one phenolic compound selected from: tyrosol, chlorogenic acid, β-hydroxyverbascoside, rutin, verbascoside, and luteolin; and/or at least one metal selected from: sodium, calcium, magnesium and potassium; and/or at least an anion selected from: chlorides, sulphates, phosphates and nitrates; and/or at least one carbohydrate selected from: glucose, fructose, mannitol and sucrose; and/or nitrogen.

### Claim 19 (depends on 10)

The method according to claim 10, wherein the concentrate further comprises: at least one phenolic compound selected from: tyrosol, chlorogenic acid, β-hydroxyverbascoside, rutin, verbascoside, and luteolin; and/or at least one metal selected from: sodium, calcium, magnesium and potassium; and/or at least an anion selected from: chlorides, sulphates, phosphates and nitrates; and/or at least one carbohydrate selected from: glucose, fructose, mannitol and sucrose; and/or nitrogen.
